Logo

BCTX

BriaCell Therapeutics Corp.

BCTX

BriaCell Therapeutics Corp. • NASDAQ
$9.70 ▼ -5.73% (-0.59)
Market Cap $18.27 M
52w High $98.20
52w Low $3.50
Dividend Yield 0%
P/E -0.16
Volume 55.12K
Outstanding Shares 1.88M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2025 $0 $11.653M ▲ $-11.057M ▼ 0% $-5.87 ▲ $-11.12M ▼
Q3-2025 $0 $8.965M ▼ $-8.717M ▲ 0% $-23.33 ▲ $-8.766M ▲
Q2-2025 $0 $10.289M ▲ $-9.063M ▼ 0% $-33.57 ▲ $-9.091M ▼
Q1-2025 $0 $6.99M ▼ $-7.912M ▼ 0% $-44.55 ▼ $-7.913M ▼
Q4-2024 $0 $7.842M $-1.672M 0% $-13.91 $-1.62M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $17.828M ▲ $21.604M ▼ $4.307M ▼ $17.843M ▲
Q3-2025 $17.215M ▲ $23.49M ▲ $6.992M ▼ $17.153M ▲
Q2-2025 $7.389M ▼ $13.8M ▼ $9.044M ▼ $5.31M ▼
Q1-2025 $8.063M ▲ $14.497M ▲ $9.328M ▼ $5.627M ▲
Q4-2024 $1.197M $8.152M $11.879M $-3.307M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2025 $-11.057M ▼ $-11.204M ▼ $-10.251M ▼ $18.683M ▼ $-2.756M ▼ $-11.204M ▼
Q3-2025 $-8.717M ▲ $-10.105M ▼ $-147.901K ▼ $20.704M ▲ $10.329M ▲ $-10.105M ▼
Q2-2025 $-9.063M ▼ $-8.551M ▲ $-107.972K ▼ $7.695M ▼ $-1.174M ▼ $-8.551M ▲
Q1-2025 $-7.912M ▼ $-9.484M ▼ $-102.275K ▲ $16.31M ▲ $6.862M ▲ $-9.485M ▼
Q4-2024 $-1.672M $-5.654M $-625.773K $6.038M $-98K $-6.279M

Five-Year Company Overview

Income Statement

Income Statement BriaCell has been a pure research company so far, with no product sales and only recurring operating losses. Those losses have been relatively small in absolute terms but very consistent, reflecting ongoing spending on trials, staff, and overhead without any offsetting revenue. The large swings in per‑share results mainly reflect repeated reverse stock splits rather than changes in the underlying business. Overall, the income statement is typical of an early‑stage biotech: all costs, no commercial income yet, and results heavily tied to R&D progress and financing conditions.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a small base of assets and most of that historically held as cash. Cash levels have trended down over time, then ticked up recently, suggesting periodic capital raises to keep funding operations. The company carries no financial debt, which reduces interest burden but also underlines that equity has been the primary funding tool. Equity has been thin and even dipped negative at one point, highlighting how fragile the capital base is and how dependent the company is on continued access to new funding as it moves through late‑stage trials.

Cash Flow

Cash Flow Cash flow is dominated by a steady, modest cash burn from operations, reflecting spending on clinical trials and corporate expenses. There is essentially no investment in physical assets, so free cash flow is almost the same as operating cash flow and consistently negative. This pattern is typical for a clinical‑stage biotech: cash only flows out until a product is approved or a partnership brings in funding. The company’s survival and ability to advance its pipeline depend on raising fresh capital or signing deals, since its operations do not generate cash on their own.

Competitive Edge

Competitive Edge BriaCell operates in a very competitive arena: cancer immunotherapy, where many large pharmaceutical and biotech companies are investing heavily. Its niche is a personalized yet “off‑the‑shelf” cell‑based approach for hard‑to‑treat cancers, especially advanced breast cancer. The technology and clinical data so far, along with fast‑track status, offer differentiation and some early credibility. However, its small size, limited resources, and lack of an approved product place it at a disadvantage compared with larger players, making partnerships, trial outcomes, and execution critical to sustaining any edge it has built.

Innovation and R&D

Innovation and R&D The company is highly innovation‑driven, with its value centered on a few key programs. Bria‑IMT, the lead cell‑based cancer vaccine, is already in a pivotal Phase 3 trial and has regulatory fast‑track status, which is a meaningful milestone for a biotech of this size. The Bria‑OTS platform aims to deliver personalized treatment without custom manufacturing, and next‑generation versions plus extensions into other cancers (like prostate) broaden the opportunity if they work as hoped. Additional small‑molecule programs and AI‑based discovery collaborations add optionality. All of this is promising but also binary: success depends on clinical trial results, regulatory decisions, and the ability to keep funding these projects through to key data readouts.

Summary

BriaCell is a classic clinical‑stage biotech: no revenue, ongoing cash burn, and a very small but debt‑free balance sheet, all tied to the fate of a focused cancer immunotherapy platform. Financially, it relies on external funding and has used reverse splits to manage its share structure, which signals ongoing dilution risk and sensitivity to market sentiment. Strategically, its personalized off‑the‑shelf immunotherapy and advancing Phase 3 program address a serious medical need and are backed by patents and encouraging early data, but they operate in a crowded oncology field dominated by much larger competitors. The company’s future will largely hinge on trial outcomes, regulatory pathways, and its ability to secure enough capital or partnerships to reach potential commercialization, making both its upside and its risks unusually concentrated around a small number of key scientific and clinical milestones.

NEWS

November 25, 2025 · 7:30 AM UTC

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Read more

November 20, 2025 · 7:30 AM UTC

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Read more

November 18, 2025 · 7:30 AM UTC

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Read more

November 7, 2025 · 7:30 AM UTC

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Read more

November 4, 2025 · 7:30 AM UTC

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Read more